Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

NCT00084513 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL: trastuzumab
DRUG: imatinib mesylate

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]